animal model comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also dissolves in common polar solvents |
| Storage temperature | Minus 20 degrees Celsius or lower | Applies to dry powder, desiccated and dark |
| Typical analytical methods | Reversed-phase HPLC and mass spectrometry | Used together for purity and identity |
| Primary degradation route | Hydrolysis and aggregation | No cysteine present, so disulfide formation is unlikely |
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
=== Metalloproteins === Metalloproteins are conjugated proteins that are characterized by having one or more metal ions attached to the protein as a prosthetic groups. These metal ions could be iron, zinc, copper, magnesium, etc., and these are very important to the biological functions and its protein activity. Metalloproteins are involved in a wide range processes from electron transfer to catalysis. Many enzymes are metalloproteins, since metal ions can act as cofactors in chemical reactions. For example, zinc ions can be associated with enzymes that are responsible for gene expression. Moreover, metalloproteins containing iron often are involved in oxygen transport and redox reactions. In this way, the presence of metal ions allows these proteins to perform certain tasks that would not be possible with amino acids alone.
By the subsequent Potsdam Agreement, the four Allied Powers asserted joint sovereignty over "Germany as a whole", defined as the totality of the territory within the occupation zones. Former German areas east of the rivers Oder and Neisse and outside of 'Germany as a whole' were officially separated from German sovereignty in August 1945 and transferred from Soviet military occupation to Polish and Soviet (in the case of the territory of Kaliningrad) civil administration, their Polish and Soviet status to be confirmed at a final Peace Treaty. Following wartime commitments by the Allies to the governments-in-exile of Czechoslovakia and Poland, the Potsdam Protocols also agreed to the 'orderly and humane' transfer to Germany as a whole of the ethnic German populations in Poland, Czechoslovakia and Hungary. Eight million German expellees and refugees eventually settled in West Germany. Between 1946 and 1949, three of the occupation zones began to merge. First, the British and American zones were combined into the quasi-state of Bizonia. Soon afterwards, the French zone was included into Trizonia. Conversely, the Soviet zone became East Germany. At the same time, new federal states (Länder) were formed in the Allied zones; replacing the geography of pre-Nazi German states such as the Free State of Prussia and the Republic of Baden, which had derived ultimately from former independent German kingdoms and principalities.
==== MeSH D12.776.402.300.700 – ras guanine nucleotide exchange factors ==== MeSH D12.776.402.300.700.500 – ras-GRF1 MeSH D12.776.402.300.700.700 – son of sevenless proteins MeSH D12.776.402.300.700.700.330 – sos1 protein MeSH D12.776.402.300.700.700.600 – son of sevenless protein, drosophila
ABT-724 is a drug which acts as a dopamine agonist, and is selective for the D4 subtype. It was developed as a possible drug for the treatment of erectile dysfunction, although poor oral bioavailability means alternative drugs such as ABT-670 may be more likely to be developed commercially. Nonetheless, it continues to be used in scientific research into the function of the D4 receptor.
Sources: en.wikipedia.org
=== Modern cereal === Over 2016 to 2017, Americans purchased 3.1 billion boxes of cereal, mostly as ready to eat cold cereal. In a $9.8 billion cereal market, cold cereal purchases were 88% of the total (12% for hot cereals), with the overall cereal market declining due to reduced consumption of sugar and dairy products. Kellogg's and General Mills each had 30% of the market share for cold cereals. Honey Nut Cheerios was the leading cold cereal.
Following the referral, the Court of Appeal began to re-examine Norris' case in May 2025. The renewed appeal was described as being of interest to lawyers acting for Lucy Letby due to her case involving similar concerns about the reliability of insulin testing and expert evidence, though the Court of Appeal would later give an oblique warning against drawing such parallels when handing down its judgement. Norris was represented during the fourteen-day hearing by Michael Mansfield KC. The court reserved judgement on 6 June 2025 and then rejected Norris' appeal on 26 June, holding that there was "no doubt" about his conviction. Norris' lawyers subsequently attempted to have an unspecified point of law certified by the Supreme Court, but the required permission was denied by the Court of Appeal in September 2025.
Early in the twentieth century Walter Cannon, who had popularized the idea of a sympathoadrenal system preparing the body for fight and flight, and his colleague Arturo Rosenblueth developed a theory of two sympathins, sympathin E (excitatory) and sympathin I (inhibitory), responsible for these actions. The Belgian pharmacologist Zénon Bacq as well as Canadian and U.S. pharmacologists between 1934 and 1938 suggested that noradrenaline might be a sympathetic transmitter. In 1939, Hermann Blaschko and Peter Holtz independently identified the biosynthetic mechanism for norepinephrine in the vertebrate body. In 1945 Ulf von Euler published the first of a series of papers that established the role of norepinephrine as a neurotransmitter. He demonstrated the presence of norepinephrine in sympathetically innervated tissues and brain, and adduced evidence that it is the sympathin of Cannon and Rosenblueth. Stanley Peart was the first to demonstrate the release of noradrenaline after the stimulation of sympathetic nerves.
Sources: en.wikipedia.org
== History == MMDA was first synthesized and studied by Gordon Alles at the Edgewood Arsenal in the mid-1950s. Its Edgewood Arsenal code name is unknown. Subsequently, Alexander Shulgin synthesized MMDA in 1962 and discovered its psychoactive effects that same year. Shulgin published his findings on MMDA in the scientific literature in 1964. Use of MMDA in psychedelic-assisted psychotherapy was studied by Shulgin, Thornton Sargent, and Claudio Naranjo in the mid-1960s and their findings were published in 1973. Naranjo also described MMDA for these purposes in his 1973 book The Healing Journey: New Approaches to Consciousness. Shulgin subsequently further described MMDA in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.
The award recognizes late career stage faculty with outstanding scientific achievement and a strong history of leadership in mentoring the careers of men and women in science. This award emphasizes leadership and support of marginalized groups.
The joint mantle plume/hotspot hypothesis originally envisaged the feeder structures to be fixed relative to one another, with the continents and seafloor drifting overhead. The hypothesis thus predicts that time-progressive chains of volcanoes are developed on the surface. Examples include Yellowstone, which lies at the end of a chain of extinct calderas, which become progressively older to the west. Another example is the Hawaiian archipelago, where islands become progressively older and more deeply eroded to the northwest. Geologists have tried to use hotspot volcanic chains to track the movement of the Earth's tectonic plates. This effort has been vexed by the lack of very long chains, by the fact that many are not time-progressive (e.g. the Galápagos) and by the fact that hotspots do not appear to be fixed relative to one another (e.g. Hawaii and Iceland). That mantle plumes are much more complex than originally hypothesised and move independently of each other and plates is now used to explain such observations. In 2020, Wei et al. used seismic tomography to detect the oceanic plateau, formed about 100 million years ago by the hypothesized mantle plume head of the Hawaii-Emperor seamount chain, now subducted to a depth of 800 km under eastern Siberia.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.
Cold, dry, and dark conditions are standard, typically at or below minus twenty degrees Celsius for long-term holding. Vials are usually warmed to room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is generally avoided.
This depends on pH, buffer, and concentration, with acidic conditions often reported as more favorable. Hydrolysis accelerates at room temperature, so solutions are commonly prepared fresh or stored frozen in single-use aliquots. No single shelf life applies across formulations.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.